Over 6 million new cases of sexually transmitted human papillomavirus (HPVs) infections are reported every year making HPV the most common sexually transmitted agent world-wide. At least 15 carcinogenic HPV types cause virtually all cervical cancers however;the costly HPV vaccine licensed in 2006 covers only HPV types 6/11/16/18 and has no therapeutic effect on established infections. Thus all women must continue routine cervical screening at a US cost of $4-5 billion annually. More importantly, the majority of women alive today are still at risk for developing cervical cancer. In addition, the current vaccine program presently leaves all men unprotected. Given these considerations and the fact that cervical cancer is a disease of disparities, it is unlikely that projected disease reductions will be realized with current strategies. Programs to characterize current US HPV vaccine implementation and effectiveness are needed and continuing efforts to better understand HPV biology and to develop broadly protective prevention strategies and therapeutics for existing infections remain critical.
The specific aims of this application are: 1) To establish the University of New Mexico Interdisciplinary HPV Prevention Center that incorporates research approaches to address these gaps in knowledge. 2) To fund and support 4 projects representing a spectrum of interdisciplinary approaches including: A) modeling of PV-host interactions in 3 dimensions to define elements of epithelial cell biology and immunity that contribute to the pathogenesis and prevention of infections;B) utilizing novel vaccine strategies based on virus-display technology to generate broad protection against a majority of HPV infections;C) utilizing a unique bioinformatics system that captures all events of a US population-based cervical screening program to characterize implementation and effectiveness of primary and secondary HPV interventions;and D) developing a set of web-based tools to promote the informed adoption of HPV and other STI prevention. 3) To establish 2 cores housing shared resources to support these interdisciplinary research approaches: A) a biostatistics and bioinformatics core and B) a virus infection core supporting technologies for virus production, quantitation, and animal imaging and housing a biospecimen resource.

Public Health Relevance

The University of New Mexico Interdisciplinary STI Prevention Center will focus on the most common sexually transmitted agents, human papillomavirus (HPV) infections. To maximally realize improvements in HPV prevention, the Center will partner basic biological discovery, technological advancements, population-based effectiveness and diffusion of interventions across laboratory, clinical &real-world settings.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI084081-04
Application #
8318763
Study Section
Special Emphasis Panel (ZAI1-MMT-M (M1))
Program Officer
Rogers, Elizabeth
Project Start
2009-09-15
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$2,899,170
Indirect Cost
$939,702
Name
University of New Mexico Health Sciences Center
Department
Pathology
Type
Schools of Medicine
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Dareng, E O; Ma, B; Famooto, A O et al. (2016) Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women. Epidemiol Infect 144:123-37
Starling, Randall; Nodulman, Jessica A; Kong, Alberta S et al. (2015) Usability Testing of an HPV Information Website for Parents and Adolescents. Online J Commun Media Technol 5:184-203
Nodulman, Jessica A; Starling, Randall; Kong, Alberta S et al. (2015) Investigating stakeholder attitudes and opinions on school-based human papillomavirus vaccination programs. J Sch Health 85:289-98
Stoler, Mark H; Ronnett, Brigitte M; Joste, Nancy E et al. (2015) The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status. Am J Surg Pathol 39:729-36
Tumban, Ebenezer; Muttil, Pavan; Escobar, Carolina Andrea A et al. (2015) Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Vaccine 33:3346-53
Cuzick, Jack; Myers, Orrin; Hunt, William C et al. (2015) Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management. Int J Cancer 136:2854-63
Joste, Nancy E; Ronnett, Brigitte M; Hunt, William C et al. (2015) Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 24:230-40
Starling, Randall; Nodulman, Jessica A; Kong, Alberta S et al. (2014) Beta-test Results for an HPV Information Web site: GoHealthyGirls.org - Increasing HPV Vaccine Uptake in the United States. J Consum Health Internet 18:226-237
Wheeler, Cosette M; Hunt, William C; Cuzick, Jack et al. (2014) The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States. Int J Cancer 135:624-34
Tyler, Mitchell; Tumban, Ebenezer; Dziduszko, Agnieszka et al. (2014) Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine 32:4267-74

Showing the most recent 10 out of 31 publications